CLOV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Clover Health Investments Corp (CLOV) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown significant revenue growth and is moving towards profitability, the stock's technical indicators, insider selling trends, and lack of strong trading signals suggest caution. Additionally, the analyst's neutral rating and lowered price target further reinforce a hold recommendation.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 48.996, and moving averages are converging, showing no clear trend. The stock closed below the pivot level of 2.08, with support at 1.958 and resistance at 2.202. Overall, the technical indicators suggest a lack of strong upward momentum.
Clover Health has partnered with Kno2 to enhance data interoperability, which could improve operational efficiency. The company achieved adjusted EBITDA profitability in 2025 and expects GAAP net income profitability in 2026, signaling progress towards financial stability.
Insider selling has increased significantly (2110.68% over the last month), which may indicate a lack of confidence from those closest to the company. UBS lowered its price target to $2.75, reflecting a reassessment of the company's valuation. The stock has also seen a regular market price decline of 4.17%.
In Q3 2025, Clover Health reported a 50.05% YoY revenue increase to $496.65 million, with net income improving to -$24.38 million (up 166.27% YoY). EPS improved to -0.05 (up 150% YoY). While these figures show strong growth, the company is still not profitable on a GAAP basis.
UBS analyst Jonathan Yong maintains a Neutral rating on CLOV and has lowered the price target from $3 to $2.75, indicating cautious sentiment from analysts.
